Ömer UYSAL, Ezgi Başak ERDOĞAN, Beril GÜLER, Adile ADİLİ

Can PET-CT replace bone marrow biopsy for lymphomastaging? Retrospective analysis of 198 Hodgkin andnon-Hodgkin lymphoma cases

Aim: Lymphoma staging is important from the prognostic and therapeutic point of view and bone marrow biopsy performed for thispurpose makes up a large part of current hematopathology practice. PET-CT is the currently preferred method to evaluate bonemarrow involvement by lymphoproliferative disorders as it is non-invasive and practical. The aim of this study was to comparetrephine biopsy and PET-CT results as regards determining bone marrow involvement in various lymphoma subtypes. Materials and Methods: A total number of 198 bone marrow biopsies and 185 PET-CT images of cases consisting of variouslymphoma subtypes were included in the study. The results of both methods evaluated for bone marrow infiltration were groupedas positive, negative, and suspicious to compare consistency. Statistical agreement was calculated with the kappa coefficient. Thesensitivity, specificity, and the positive and negative predictive values were calculated as the diagnostic test measures.Results: Twenty-six cases (15.8%) had lymphoma involvement in trephine biopsies and 36 cases (21.2%) had positive findings forlymphoma involvement of the bone marrow on PET-CT. The two methods had weak statistical agreement (κ= 0.21). Biopsy and PET CT results were similar in 132 cases (71.20%). PET-CT showed false negative results in 11 cases in which infiltration was observedwith biopsy. Twenty-six cases that were negative for lymphoma involvement on biopsy were accepted as positive on PET-CT and 16of these cases were classical Hodgkin's lymphoma. One case with suspicious bone marrow biopsy was positive on PET-CT, whilefour cases with suspicious PET-CT results were positive on biopsy. Conclusion: The results showed that both of the methods have advantages and disadvantages as regards lymphoma staging.However, histopathology is globally accepted as the gold standard for a definite diagnosis. We believe that the complementary useof the two methods is more beneficial for correct guidance during clinical practice.

PDF

___

1. Ansel SM. Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clin Proc 2015;90:1574-83.
2. Ansel SM. Non-Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clin Proc 2015;90:1152-63.
3. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059.
4. Makita S, Maruyama D, Maeshima AM, et al. A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma. Asia Pac J Clin Oncol 2020;16:108-14.
5. Cheson BD. Bone Marrow Biopsy for the Initial Staging of Patients With Lymphoma: It’s Time to Eliminate This Procedure in Selected Patients. Oncology 2013;27:1289-92.
6. El-Galaly TC, d’Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/ computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012;30:4508-14.
7. Teagle AR, Barton H, Charles-Edwards E, et al. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy. Acta Radiologica 2017;58:1476-84.
8. Xiao-Xue W, Xinyue H, Lijun Z. Whole body FDG-PET/ CT for the assessment of bone marrow infiltration in patients with newly diagnosed lymphoma. Med Clin (Barc) 2020;154:61-5.
9. Cortés-Romera M, Sabaté-Llobera A, MercadalVilchez S, et al. Bone marrow evaluation in initial staging of lymphoma: 18F-FDG PET/CT versus bone marrow biopsy. Clin Nucl Med 2014;39:46-52.
10. Kim HY, Kim J-S, Choi DR, et al. The clinical utility of FDG PET-CT in evaluation of bone marrow involvement by lymphoma. Cancer Res Treat 2015;47:458-64.
11. Oner AO, Surer Budak E, Aydin F, et al. FDG-PET/CT Efficiency for Bone Marrow Infiltration Assessment in Initial Staging of Lymphoma. Mol Imaging Radionucl Ther 2017;26:69-75.
12. Wu Y, Su L, Yang X, et al. Preliminary evaluation of PET-CT and DWI for the detection of lymphoma bone marrow infiltration. Zhonghua Zhong Liu Za Zhi 2016;38:853-60.
13. Adams HJ, de Klerk JM, Fijnheer R, et al. Variety in bone marrow 18F-FDG uptake in Hodgkin lymphoma patients without lymphomatous bone marrow involvement: does it have an explanation? Nucl Med Commun 2016;37:23-9.
14. Lakhwani S, Cabello-García D, Allende-Riera A, et al. Bone marrow trephine biopsy in Hodgkin's lymphoma. Comparison with PET–CT scan in 65 patients. Med Clin (Barc) 2018;150:104-6.
15. Pedersen MA, Gormsen LC, d'Amore F. Value of detecting bone marrow involvement in Hodgkin lymphoma-Response to Adams and Kwee. Br J Haematol 2019;187:396-7.
16. Avigdor A. Staging DLBCL: bone marrow biopsy or PET-CT? Blood 2013;122:4-5.
17. El Karak F, Bou-Orm IR, Ghosn M, et al. PET/CT scanner and bone marrow biopsy in detection of bone marrow involvement in diffuse large B-cell lymphoma. PLoS One 2017;12:e0170299.
18. Ujjani CS, Hill EM, Wang H, et al. 18F-FDG PETCT and trephine biopsy assessment of bone marrow involvement in lymphoma. Br J Haematol 2016;174:410-6.
19. Morgan R, Perry M, Kwak J, et al. Positron Emission Tomography-based Analysis Can Accurately Predict Bone Marrow Involvement With Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk 2018;18:731-6.
20. Feng M, Yang X, Ma Q, et al. Retrospective analysis for the false positive diagnosis of PET-CT scan in lung cancer patients. Medicine (Baltimore) 2017;96:7415.
21. Niyonkuru A, Chen X, Bakari KH, et al. Evaluation of the diagnostic efficacy of 18F-Fluorine-2-DeoxyD-Glucose PET/CT for lung cancer and pulmonary tuberculosis in a Tuberculosis-endemic Country. Cancer Med 2020;9:931-42.
22. Okuyama C, Higashi T, Nakamoto R, et al. Predominance and homogeneity patterns of physiological FDG accumulation in thoracic and lumbar vertebrae: suspected mechanism of “bone pseudometastasis” on FDG-PET in Japanese patients with esophageal cancer. Ann Nucl Med 2020;34:182-91.
23. Chong A, Song H-C, Oh J-R, et al. Gelatinous degeneration of the bone marrow mimicking osseous metastasis on 18F-FDG PET/CT. Clin Nucl Med 2012;37:798-800.
24. Norikane T, Yamamoto Y, Mitamura K, et al. FalsePositive 18F-FDG and 18F-Fluorothymidine Uptake in a Patient With Round Atelectasis. Clin Nucl Med 2020;45:158-9.
25. Okubo A, Fujii K, Tada K, et al. Acne vulgaris with falsepositive signals on 18 F-fluorodeoxyglucose positron emission tomography-computed tomography in a patient with a yolk sac tumor. J Dermatol 2020;47:33- 34.
26. Berger A. How does it work?: Positron emission tomography. BMJ 2003;326:1449.
27. Howell SJ, Grey M, Chang J, et al. The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre. Br J Haematol 2002;119:408-11.
28. Sultan S, Irfan SM, Parveen S, et al. Frequency and Pattern of Bone Marrow Infiltration in Classical Hodgkin's Lymphoma: Experience from Southern Pakistan. Asian Pac J Cancer Prev 2016;17:1857-9.
29. Chen-Liang TH, Martín-Santos T, Jerez A, et al. Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma. Cancer Med 2017;6:2507-14.
30. Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011;29:1452-7.